60 studies found for:    Open Studies | "Oropharyngeal Neoplasms"
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "Oropharyngeal Neoplasms"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Unknown  Cetuximab & Concomitant-Boost Accelerated RT in Patients With Locally Advanced Oropharynx Squamous Cell Carcinoma.
Condition: Oropharyngeal Neoplasms
Intervention: Drug: Cetuximab
2 Recruiting De-intensification of Radiation and Chemotherapy for Low-Risk HPV-related Oropharyngeal SCC: Follow-up Study
Conditions: Carcinoma, Squamous Cell;   Head and Neck Neoplasms;   Oropharyngeal Neoplasms
Interventions: Radiation: Intensity Modulated Radiotherapy (IMRT);   Drug: Cisplatin (or alternative);   Procedure: Assessment for surgical evaluation
3 Not yet recruiting Paclitaxel, Cisplatin and BYL719 for HPV-Associated Oropharyngeal Squamous Cell Carcinoma
Conditions: Carcinoma, Squamous;   Squamous Cell Carcinoma;   Oropharyngeal Neoplasms;   Oropharyngeal Cancer
Interventions: Drug: cisplatin;   Drug: paclitaxel;   Drug: BYL719
4 Recruiting Post Operative Adjuvant Therapy De-intensification Trial for Human Papillomavirus-related, p16+ Oropharynx Cancer
Condition: Oropharyngeal Neoplasms
Interventions: Radiation: Intensity-modulated radiation therapy (IMRT);   Drug: Cisplatin
5 Recruiting A Post-Market Clinical Trial for Access and Visualization of the Oropharynx and Hypopharynx During Transoral Procedures
Conditions: OSA;   Oral Disease;   Oropharyngeal Neoplasms;   Hypopharyngeal Neoplasms
Intervention:
6 Unknown  Analgesia of Fibula Free Flap Donor Site by Peri-Neuronal Catheter in Oro-Pharyngeal Carcinoma Surgery
Condition: Oropharyngeal Neoplasms
Intervention: Device: Peri-Neuronal Catheter
7 Recruiting A Phase II Study In Patients With Advanced Head And Neck Cancer Of Standard Chemoradiation And Add-On Cetuximab
Conditions: Oropharyngeal Cancer;   Hypopharyngeal Cancer;   Laryngeal Cancer
Intervention: Drug: Cetuximab
8 Not yet recruiting Establishing Lymphedema and Fibrosis Measures in Oral Cancer Patients
Conditions: Oral Cavity Cancer;   Oropharyngeal Cancer;   Lymphedema;   Fibrosis
Interventions: Other: LEF measures;   Procedure: Technical measure
9 Recruiting A Phase II Randomized Trial for Early-stage Squamous Cell Carcinoma of the Oropharynx: Radiotherapy vs Trans-oral Robotic Surgery (ORATOR)
Condition: Early-Stage Squamous Cell Carcinoma of the Oropharynx
Interventions: Radiation: Radiotherapy;   Procedure: Transoral Robotic Surgery + Neck Dissection
10 Recruiting Acupuncture in Reducing the Severity of Chemoradiation-induced Mucositis in Patients With Oropharyngeal Cancer
Conditions: Mucositis;   Oropharyngeal Cancer
Interventions: Device: Acupuncture with Seirin® needles;   Other: Usual medical care
11 Recruiting Neoadjuvant Erbitux Based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer
Conditions: Locally Advanced Malignant Neoplasm;   Oral Cancer;   Oropharyngeal Carcinoma;   Effects of Chemotherapy
Intervention: Drug: Neo-adjuvant Erbitux-based chemotherapy
12 Recruiting Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer
Conditions: Human Papilloma Virus Infection;   Stage III Squamous Cell Carcinoma of the Oropharynx;   Stage IVA Squamous Cell Carcinoma of the Oropharynx;   Stage IVB Squamous Cell Carcinoma of the Oropharynx
Interventions: Procedure: therapeutic conventional surgery;   Radiation: intensity-modulated radiation therapy;   Drug: cisplatin;   Drug: carboplatin;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment
13 Recruiting A Single-arm Phase II Study of Post-Transoral Robotic Surgery (TORS) Alone to the Primary Tumor Site and Selective Neck Dissection (SND) Followed by Adjuvant Radiation Therapy (+/- Chemotherapy) to the Regional Nodes for Advanced Stage, Human Papilloma Virus (HPV) Positive, Oropharyngeal Cancer
Condition: Oropharyngeal Cancer
Interventions: Procedure: TORS;   Radiation: Adjuvant Radiation Therapy
14 Recruiting A Phase 1 Dose Escalation Study of GC4419 in Combination With Chemoradiation for Squamous Cell Cancer of the Head & Neck
Conditions: Squamous Cell Carcinoma of the Oral Cavity;   Squamous Cell Carcinoma of the Oropharynx
Intervention: Drug: GC4419
15 Recruiting Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating Patients With Recurrent Head and Neck Cancer
Conditions: Recurrent Salivary Gland Cancer;   Recurrent Squamous Cell Carcinoma of the Hypopharynx;   Recurrent Squamous Cell Carcinoma of the Larynx;   Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Nasopharynx;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Verrucous Carcinoma of the Larynx;   Recurrent Verrucous Carcinoma of the Oral Cavity;   Salivary Gland Squamous Cell Carcinoma;   Tongue Cancer
Interventions: Drug: carboplatin;   Drug: paclitaxel albumin-stabilized nanoparticle formulation;   Drug: fluorouracil;   Drug: hydroxyurea;   Procedure: therapeutic conventional surgery;   Radiation: radiation therapy;   Radiation: hyperfractionated radiation therapy;   Other: laboratory biomarker analysis
16 Recruiting Paclitaxel and Carboplatin Before Radiation Therapy With Paclitaxel in Treating HPV-Positive Patients With Stage III-IV Oropharynx, Hypopharynx, or Larynx Cancer
Conditions: Human Papilloma Virus Infection;   Stage III Squamous Cell Carcinoma of the Hypopharynx;   Stage III Squamous Cell Carcinoma of the Larynx;   Stage III Squamous Cell Carcinoma of the Oropharynx;   Stage III Verrucous Carcinoma of the Larynx;   Stage IV Squamous Cell Carcinoma of the Hypopharynx;   Stage IV Verrucous Carcinoma of the Larynx;   Stage IVA Squamous Cell Carcinoma of the Larynx;   Stage IVA Squamous Cell Carcinoma of the Oropharynx;   Stage IVA Verrucous Carcinoma of the Larynx;   Stage IVB Squamous Cell Carcinoma of the Larynx;   Stage IVB Squamous Cell Carcinoma of the Oropharynx;   Stage IVB Verrucous Carcinoma of the Larynx;   Stage IVC Squamous Cell Carcinoma of the Larynx;   Stage IVC Squamous Cell Carcinoma of the Oropharynx;   Stage IVC Verrucous Carcinoma of the Larynx
Interventions: Drug: paclitaxel;   Drug: carboplatin;   Radiation: intensity-modulated radiation therapy;   Procedure: quality-of-life assessment
17 Not yet recruiting HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA
Conditions: Human Papillomavirus-Related Carcinoma;   Human Papillomavirus Positive Oropharyngeal Carcinoma;   Human Papillomavirus Positive Cervical Carcinoma;   Human Papillomavirus Positive Anal Carcinoma;   Human Papillomavirus Positive Vulvar Carcinoma;   Human Papillomavirus Positive Penile Carcinoma
Intervention: Genetic: HPV Specific T Cells
18 Unknown  Safety Study of Recombinant Listeria Monocytogenes(Lm)Based Vaccine Virus Vaccine to Treat Oropharyngeal Cancer
Condition: HPV-16 +ve Oropharyngeal Carcinoma
Intervention: Biological: ADXS11-001
19 Recruiting PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Conditions: Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma;   Recurrent Metastatic Squamous Neck Cancer With Occult Primary;   Recurrent Salivary Gland Cancer;   Recurrent Squamous Cell Carcinoma of the Hypopharynx;   Recurrent Squamous Cell Carcinoma of the Larynx;   Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Nasopharynx;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Verrucous Carcinoma of the Larynx;   Recurrent Verrucous Carcinoma of the Oral Cavity;   Salivary Gland Squamous Cell Carcinoma;   Stage IV Squamous Cell Carcinoma of the Hypopharynx;   Stage IV Squamous Cell Carcinoma of the Nasopharynx;   Stage IVA Salivary Gland Cancer;   Stage IVA Squamous Cell Carcinoma of the Larynx;   Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVA Squamous Cell Carcinoma of the Oropharynx;   Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVA Verrucous Carcinoma of the Larynx;   Stage IVA Verrucous Carcinoma of the Oral Cavity;   Stage IVB Salivary Gland Cancer;   Stage IVB Squamous Cell Carcinoma of the Larynx;   Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVB Squamous Cell Carcinoma of the Oropharynx;   Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVB Verrucous Carcinoma of the Larynx;   Stage IVB Verrucous Carcinoma of the Oral Cavity;   Stage IVC Salivary Gland Cancer;   Stage IVC Squamous Cell Carcinoma of the Larynx;   Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVC Squamous Cell Carcinoma of the Oropharynx;   Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVC Verrucous Carcinoma of the Larynx;   Stage IVC Verrucous Carcinoma of the Oral Cavity;   Tongue Cancer
Interventions: Drug: PI3K inhibitor BKM120;   Biological: cetuximab;   Other: laboratory biomarker analysis;   Other: questionnaire administration
20 Recruiting Patient Preferences in Making Treatment Decisions in Patients With Stage I-IVA Oropharyngeal Cancer
Conditions: Stage I Squamous Cell Carcinoma of the Oropharynx;   Stage II Squamous Cell Carcinoma of the Oropharynx;   Stage III Squamous Cell Carcinoma of the Oropharynx;   Stage IVA Squamous Cell Carcinoma of the Oropharynx;   Tongue Cancer
Interventions: Other: questionnaire administration;   Procedure: quality-of-life assessment

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years